

# Retinoic Acid Receptor Alpha - Pipeline Review, H2 2019

<https://marketpublishers.com/r/R7A7FA894321EN.html>

Date: November 2019

Pages: 68

Price: US\$ 3,500.00 (Single User License)

ID: R7A7FA894321EN

## Abstracts

Retinoic Acid Receptor Alpha - Pipeline Review, H2 2019

### SUMMARY

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Retinoic acid receptor alpha (RARA) is a nuclear receptor that is encoded by the RARA gene. RARA plays an essential role in the regulation of retinoic acid-induced germ cell development during spermatogenesis. It promotes the survival and development of early meiotic prophase spermatocytes. It regulates expression of target genes in a ligand-dependent manner by recruiting chromatin complexes containing KMT2E/MLL5 and mediates retinoic acid-induced granulopoiesis.

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) pipeline Target constitutes close to 12 molecules. Out of which approximately 12 molecules are developed by Companies. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 2, 4 and 1 respectively. Report covers products from therapy areas Dermatology, Oncology, Respiratory, Central Nervous System, Gastrointestinal, Hematological Disorders, Immunology and Ophthalmology which include indications Acne Vulgaris, Bronchopulmonary Dysplasia, Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Promyelocytic Leukemia, Batten Disease, Breast Cancer, Chronic Myelomonocytic Leukemia (CMML), Germ Cell Tumors, Inflammatory Bowel Disease, Myeloproliferative Disorders, Neuroblastoma, Neutropenia, Psoriasis, Retinopathy Of Prematurity and Sarcomas.

The latest report Retinoic Acid Receptor Alpha - Pipeline Review, H2 2019, outlays comprehensive information on the Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA)

The report reviews Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA)

targeted therapeutics and enlists all their major and minor projects

The report assesses Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Overview

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Companies Involved in Therapeutics Development

3SBio Inc

Advent Therapeutics Inc

Io Therapeutics Inc

Orphanix GmbH

Ortho Dermatologics Inc

Phosphagenics Ltd

Polaryx Therapeutics Inc

Sol-Gel Technologies Ltd

Sunny BioDiscovery Inc

TherapyX Inc

Toko Pharmaceutical Industries Co Ltd

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Drug Profiles

(benzoyl peroxide + tretinoin) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(benzoyl peroxide + tretinoin) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress  
(clindamycin phosphate + tretinoin) - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
(gemfibrozil + tretinoin) - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
(TPX-6001 + tretinoin) - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
alitretinoin - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
IRX-5183 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
SBD-073 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
tamibarotene - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
tretinoin - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
tretinoin - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
vitamin A palmitate - Drug Profile  
Product Description

Mechanism Of Action

R&D Progress

vitamin A palmitate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Dormant Products

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Discontinued Products

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Product Development Milestones

Featured News & Press Releases

Oct 24, 2019: Syros Announces new data from phase 2 trial of SY-1425 in combination with azacitidine demonstrating high response rates, rapid onset of action and favorable tolerability profile in RARA-Positive Newly Diagnosed Unfit AML Patients

Oct 15, 2019: Bausch Health's Ortho Dermatologics business to present data on acne drug tretinoin at The Fall Clinical Dermatology Conference

Aug 01, 2019: Syros highlights key accomplishments and provides milestone update on SY-1425

Jul 09, 2019: GSK's Alitoc becoming salvation treatment for chronic hand eczema patients

Apr 15, 2019: Sol-Gel Technologies announces 50% enrollment in pivotal phase III TWIN Program for the treatment of Acne Vulgaris

Jan 06, 2019: Syros provides update on its acute myeloid leukemia drug candidate SY-1425

Dec 17, 2018: Sol-Gel Technologies initiates pivotal phase III clinical program of TWIN for the treatment of acne vulgaris

Dec 02, 2018: Syros announces promising clinical data from ongoing phase 2 trial of SY-1425 in genomically defined AML and MDS patients at ASH Annual Meeting

Nov 01, 2018: Syros to present initial clinical data from combination cohorts in its ongoing phase 2 Trial of SY-1425 at ASH annual meeting

Oct 30, 2018: Bausch Health launches ALTRENO (tretinoin) Lotion, 0.05% in the United States

Oct 15, 2018: Bausch Health's ortho dermatologics business to present on ALTRENO During The Fall Clinical Dermatology Conference

Oct 11, 2018: Bausch Health announces publication of pivotal phase 3 efficacy and safety data on ALTRENO (tretinoin) Lotion, 0.05%, in the journal of drugs in dermatology

Sep 04, 2018: Sol-Gel Technologies provides program update for TWIN for the treatment of acne vulgaris

Aug 24, 2018: Ortho Dermatologics receives FDA approval for Altreno (tretinoin 0.05%) lotion for acne

Jul 10, 2018: Syros to Host Key Opinion Leader Symposium on Acute Myeloid Leukemia and Myelodysplastic Syndrome on July 17, 2018

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by 3SBio Inc, H2 2019

Pipeline by Advent Therapeutics Inc, H2 2019

Pipeline by Io Therapeutics Inc, H2 2019

Pipeline by Orphanix GmbH, H2 2019

Pipeline by Ortho Dermatologics Inc, H2 2019

Pipeline by Phosphagenics Ltd, H2 2019

Pipeline by Polaryx Therapeutics Inc, H2 2019

Pipeline by Sol-Gel Technologies Ltd, H2 2019

Pipeline by Sunny BioDiscovery Inc, H2 2019

Pipeline by TherapyX Inc, H2 2019

Pipeline by Toko Pharmaceutical Industries Co Ltd, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Discontinued Products, H2 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

### COMPANIES MENTIONED

3SBio Inc

Advent Therapeutics Inc

lo Therapeutics Inc

Orphanix GmbH

Ortho Dermatologics Inc

Phosphagenics Ltd

Polaryx Therapeutics Inc

Sol-Gel Technologies Ltd

Sunny BioDiscovery Inc

TherapyX Inc

Toko Pharmaceutical Industries Co Ltd

## I would like to order

Product name: Retinoic Acid Receptor Alpha - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/R7A7FA894321EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R7A7FA894321EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970